MESO - Mesoblast Ltd logo

Mesoblast Ltd

MESO

Mesoblast Ltd develops regenerative medicine products utilizing mesenchymal lineage cells. Its lead candidate, Remestemcel-L, targets systemic inflammatory diseases and chronic conditions. The company collaborates on various therapies for heart failure and arthritis.

βš•οΈ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago β†’$1,459today

Score Overview

1 Year
Score
Net Growth43.71%
Net TrendGrew
Net Income Consistencyβ€”
Rev Growth6x
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score5.9
Net Growth41.81%
Net Trend60%
Net Income Consistencyβ€”
Rev Growth16x
Rev Trend60%
Revenue Consistencyβ€”
10 Years
Score
Net Growth-11x
Net Trend50%
Net Income Consistency
Rev Growth182.62%
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth-11x
Net Trend50%
Net Income Consistency
Rev Growth182.62%
Rev Trend50%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Mesoblast Ltd has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. MESO does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 12.55β€”
1 Year2025-10-22
$ 17.18-26.95%
5 Years2021-10-22
$ 12.68-1.03%
10 Years2016-10-21
$ 8.6045.93%
All Time2015-11-13
$ 16.22-22.63%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
2026$ 120M-$ 57M
2025$ 17M-$ 102M$ 161M
2024$ 5M-$ 87M$ 62M
2023$ 7M-$ 81M$ 70M
2022$ 10M-$ 91M$ 60M
2021$ 7M-$ 98M$ 136M
2020$ 32M-$ 77M$ 129M
2019$ 16M-$ 89M$ 50M
2018$ 17M-$ 35M$ 37M
2017$ 2M-$ 76M$ 45M
2016$ 42M-$ 4M$ 21M
MESO - Mesoblast Ltd logo

Mesoblast Ltd fundamental performance

Between 2021 and 2026, revenue grew from $ 7M to $ 120M and net income went from -$ 98M to -$ 57M. Revenue increased in 3 of those 5 years; net income in 3.

Between 2016 and 2026, revenue grew from $ 42M to $ 120M and net income went from -$ 4M to -$ 57M. Revenue increased in 5 of those 10 years; net income in 5.

Mesoblast Ltd currently holds a 5-year HDB Score of 5.9 out of 10. How the HDB Score is calculated.

Membership

Explore MESO with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies